Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric aprepitant for prevention of chemotherapy-induced nausea and vomiting
NL-OMON37972Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing Aprepitant + ondansetron with Placebo + ondansetron control (2 arms). Primary endpoint: Complete response in overall phase. Started Nov 2011; status: active, not recruiting.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NL-OMON37972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37972.